Scientists At University Of Michigan Report Research In Colon Cancer
NewsRx.com
July 16, 2009
According to recent research from the United States, "Sunitinib is an oral small-molecule multitargeted receptor tyrosine kinase inhibitor that has recently been shown to have clinical benefit as a single agent in renal cell cancer and gastrointestinal stromal tumors, leading to its Food and Drug Administration approval for treatment of these cancers. However, the benefit is short-lived; and for the majority of cancers, sunitinib single-agent clinical activity is low."
Upcoming:
2010
- Portland, OR
- Colchester, VT
- Southeast Indiana
- Central Ohio
- Waukon, IA
- San Francisco, CA
- Austin, TX
- Des Moines, IA
- Alexandria, VA
2011
- Chattanooga, TN
- Fort Myers, FL
- Baton Rouge, LA
- Boston, MA
- Philadelphia, PA
- Winston-Salem, NC
- Wichita KS
- Cincinnati, OH
- Albany, NY
- Milwaukee, WI
- Houston TX